Abstract: Systems and methods for matching consumers with providers are provided. A method includes obtaining scheduling information and provider information associated with providers, the scheduling information comprising availability information and location information associated with each of the providers for different time blocks, and the provider information including goods or services information associated with each of the providers. The method also includes receiving a query associated with a consumer specifying a good or service to be provided to the consumer and a requested location for the providing. The method also includes generating, based on the scheduling information, a response to the query. The response can include an identification of providers available to provide the good or the service at the location and times each of the identified providers is available to provide the good or the service at the location.

Abstract: An in-flight system provides a user with an entertainment environment including movies, music, games, internet, map, etc. The in-flight system provides stored media content on one or more servers located throughout an aircraft cabin and each server is associated with a plurality of seats. In a preferred embodiment, the in-flight system provides for a communication port (e.g., USB or mini-USB connector or micro-USB connector) for connection to personal electronic device providing access to the server containing the stored media, access to an internet connection, and power. In one embodiment, the in-flight system provides for a seat display unit (typically located in the seat back of the next forward seat) and associated media module hardware to process the stored media content and drive the display.

Abstract: A hybrid continuous fermentation system and related process for fermenting sugars to produce alcohol containing liquors. The system includes a fermentor arranged with a packed bed region and a fluidized bed region. A yeast bed is retained in the packed bed region using a retention matrix and flocculation. A sugar supply is directed through the yeast bed with sufficient dwell time for satisfactory sugar conversion. The fluidized bed region is arranged to allow fermented product to pass through the fermentor while allowing yeast cell growth and retention. A nutrient may be added to the fermentor to aid in yeast flocculation. The fermentor is sized and shaped to allow sufficient dwell time of the sugar supply in the packed bed region and in the fluidized bed region to maximize sugar conversion to ethanol by fermentation.

Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.

Abstract: Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey. The tissue engineered scaffolds having a fiber support and honey can further include at least one biomolecule. The tissue engineered scaffolds can be used to promote cellular chemotaxis, enhance cell proliferation, enhance extracellular matrix production, increase angiogenesis, and provide antimicrobial activity. The nature of the tissue engineered scaffolds provides a template for cellular infiltration and guide tissue regeneration. The tissue engineered scaffolds can be used in the treatment of dermal wounds (burns, chronic wounds, etc.) or as a tissue engineering scaffold in a wide range of applications.

Abstract: An in-flight system provides a user with an entertainment environment including movies, music, games, internet, map, etc. The in-flight system provides stored media content on one or more servers located throughout an aircraft cabin and each server is associated with a plurality of seats. In a preferred embodiment, the in-flight system provides for a communication port (e.g., USB or mini-USB connector or micro-USB connector) for connection to personal electronic device providing access to the server containing the stored media, access to an internet connection, and power. In one embodiment, the in-flight system provides for a seat display unit (typically located in the seat back of the next forward seat) and associated media module hardware to process the stored media content and drive the display.

Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.

Abstract: Methods and systems for providing a passenger with a comprehensive software application that is associated with the passenger's flight plan and is spatially aware of the passenger's location and/or feedback with the application in order to assist the passenger with flight related tasks is disclosed. The method includes providing a different interactive map to each of a plurality of passengers on an aircraft can include packaging and transmitting flight specific data, graphical representation of the retrieved map imagery data, and the text layer with a server based application for receipt by a client based application for display and interaction, requiring additional packaging and transmitting. Alternative methods include providing an interactive map by requesting and receiving flight specific data and map imagery using a client based application running on a personal electronic device (PED) and then rendering and displaying the map imagery data per instructions of the client based application.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein is an isolated compound according to Formula Ia: or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein is an isolated compound according to Formula Ib: or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2?-methyl nucleotides linked according to Formula I: N1-L-N2??(I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N1, L and N2 are as described herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.